Your browser doesn't support javascript.
loading
The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.
Spinazzola, Edoardo; Quattrone, Diego; Rodriguez, Victoria; Trotta, Giulia; Alameda, Luis; Tripoli, Giada; Gayer-Anderson, Charlotte; Freeman, Tom P; Johnson, Emma C; Jongsma, Hannah E; Stilo, Simona; La Cascia, Caterina; Ferraro, Laura; La Barbera, Daniele; Lasalvia, Antonio; Tosato, Sarah; Tarricone, Ilaria; D'Andrea, Giuseppe; Galatolo, Michela; Tortelli, Andrea; Tagliabue, Ilaria; Turco, Marco; Pompili, Maurizio; Selten, Jean-Paul; de Haan, Lieuwe; Rossi Menezes, Paulo; Del Ben, Cristina M; Santos, Jose Luis; Arrojo, Manuel; Bobes, Julio; Sanjuán, Julio; Bernardo, Miguel; Arango, Celso; Kirkbride, James B; Jones, Peter B; O'Donovan, Michael; Rutten, Bart P; Van Os, Jim; Morgan, Craig; Sham, Pak C; Austin-Zimmerman, Isabelle; Li, Zhikun; Vassos, Evangelos; Murray, Robin M; Di Forti, Marta.
Afiliação
  • Spinazzola E; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
  • Quattrone D; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
  • Rodriguez V; National Institute for Health Research, Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College, London, UK.
  • Trotta G; South London and Maudsley NHS Mental Health Foundation Trust, London, UK.
  • Alameda L; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
  • Tripoli G; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
  • Gayer-Anderson C; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
  • Freeman TP; Service of General Psychiatry, Treatment and Early Intervention in Psychosis Program, Lausanne, University Hospital (CHUV), Lausanne, Switzerland.
  • Johnson EC; Centro Investigacion Biomedica en Red de Salud Mental (CIBERSAM); Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocio, Departamento de Psiquiatria, Universidad de Sevilla, Sevilla, Spain.
  • Jongsma HE; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
  • Stilo S; Biomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.
  • La Cascia C; Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Ferraro L; Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
  • La Barbera D; National Addiction Centre, Institute of Psychiatry, King's College London, London, UK.
  • Lasalvia A; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
  • Tosato S; Psylife Group, Division of Psychiatry, University College London, London, UK.
  • Tarricone I; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
  • D'Andrea G; Department of Mental Health and Addiction Services, ASP Crotone, Crotone, Italy.
  • Galatolo M; Biomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.
  • Tortelli A; Biomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.
  • Tagliabue I; Biomedicine, Neuroscience and Advanced Diagnostic Department, Psychiatry Section, University of Palermo, Palermo, Italy.
  • Turco M; Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  • Pompili M; Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  • Selten JP; Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
  • de Haan L; Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
  • Rossi Menezes P; Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
  • Del Ben CM; Institut Mondor de recherché biomedicale, Creteil, France.
  • Santos JL; Etablissement Public de Sante Maison Blanche, Paris, France.
  • Arrojo M; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
  • Bobes J; Department of Mental Health and Addiction Services, ASST Lecco, Lecco, Italy.
  • Sanjuán J; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
  • Bernardo M; Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
  • Arango C; Rivierduinen Institute for Mental Health Care, Leiden, The Netherlands.
  • Kirkbride JB; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Jones PB; Early Psychosis Section, AmsterdamUMC, Academic Medical Centre, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands.
  • O'Donovan M; Department of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, São Paulo, Brazil.
  • Rutten BP; Department of Preventive Medicine, Faculdade de Medicina, Universidade of São Paulo, São Paulo, Brazil.
  • Van Os J; Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", Cuenca, Spain.
  • Morgan C; Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain.
  • Sham PC; Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, Spain.
  • Austin-Zimmerman I; Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Valencia, Spain.
  • Li Z; Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Biomedical Research Networking Centre in Mental Health (CIBERSAM), Barcelona, Spain.
  • Vassos E; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.
  • Murray RM; Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Di Forti M; CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.
Psychol Med ; 53(15): 7418-7427, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37129249
ABSTRACT

BACKGROUND:

While cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis.

METHODS:

We used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case-control study. 558 first-episode psychosis patients (FEPp) and 567 population controls who had used cannabis and reported their RFUC.We ran logistic regressions to examine whether RFUC were associated with first-episode psychosis (FEP) case-control status. Path analysis then examined the relationship between RFUC, subsequent patterns of cannabis use, and case-control status.

RESULTS:

Controls (86.1%) and FEPp (75.63%) were most likely to report 'because of friends' as their most common RFUC. However, 20.1% of FEPp compared to 5.8% of controls reported 'to feel better' as their RFUC (χ2 = 50.97; p < 0.001). RFUC 'to feel better' was associated with being a FEPp (OR 1.74; 95% CI 1.03-2.95) while RFUC 'with friends' was associated with being a control (OR 0.56; 95% CI 0.37-0.83). The path model indicated an association between RFUC 'to feel better' with heavy cannabis use and with FEPp-control status.

CONCLUSIONS:

Both FEPp and controls usually started using cannabis with their friends, but more patients than controls had begun to use 'to feel better'. People who reported their reason for first using cannabis to 'feel better' were more likely to progress to heavy use and develop a psychotic disorder than those reporting 'because of friends'.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Cannabis / Fumar Maconha Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Psychol Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Cannabis / Fumar Maconha Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Psychol Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido